|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
NOTE 1: ORGANIZATION AND BASIS OF PRESENTATION
Organization. NovoCure Limited (including its consolidated subsidiaries, the “Company”) was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of TTFields for the treatment of solid tumors. Since inception, the Company has devoted substantially all of its efforts to developing and commercializing a family of products to deliver TTFields for a variety of solid tumor indications, raising capital and recruiting personnel. The Company has regulatory approvals and clearances in certain countries for Optune, its first TTFields delivery system, to treat glioblastoma (“GBM”). The Company commenced marketing Optune in the United States at the end of 2011, in certain countries in Europe in 2014 and in Japan in 2015.
Financial statement preparation. The accompanying condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries, and intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the “2015 10-K”) filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2016.
The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the 2015 10-K are applied consistently in these unaudited interim consolidated financial statements.
Recently Issued Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.
In March 2016, FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.
In April 2016, FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASU 2016-10 covers two specific topics: performance obligations and licensing. This amendment includes guidance on immaterial promised goods or services, shipping or handling activities, separately identifiable performance obligations, functional or symbolic intellectual property licenses, sales-based and usage-based royalties, license restrictions (time, use, geographical) and licensing renewals. In addition, in May 2016, FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The Company is currently evaluating the impact of the adoption of both revenue standards on its consolidated financial statements.
In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. ASU 2016-13 also applies to employee benefit plan accounting, with an effective date of the first quarter of fiscal 2022. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and employee benefit plans’ accounting.
In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayment or extinguishment costs, the maturing of a zero coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The retrospective transition method, requiring adjustment to all comparative periods presented, is required unless it is impracticable for some of the amendments, in which case those amendments would be prospectively adjusted as of the earliest date practicable. The standard is effective on January 1, 2019. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements.
|
NOTE 2: SHORT-TERM INVESTMENTS
The Company invests in marketable U.S. Treasury Bills (“T-bills”) that are classified as held-to-maturity securities. The amortized cost and recorded basis of the T-bills are presented as short-term investments in the amount of $119,724 and $150,001 as of September 30, 2016 and December 31, 2015, respectively, and their estimated fair value as of September 30, 2016 and December 31, 2015 was $119,604 and $149,978, respectively.
|
NOTE 3: INVENTORIES
Inventories are stated at the lower of cost or market. The weighted average methodology is applied to determine cost. As of September 30, 2016 and December 31, 2015, the Company’s inventories were composed of:
|
|
September 30, |
|
|
December 31, |
|
||
|
|
2016 |
|
|
2015 |
|
||
|
|
Unaudited |
|
|
Audited |
|
||
Raw materials |
|
$ |
4,517 |
|
|
$ |
3,518 |
|
Work in progress |
|
|
9,621 |
|
|
|
4,618 |
|
Finished products |
|
|
9,834 |
|
|
|
5,458 |
|
Total |
|
$ |
23,972 |
|
|
$ |
13,594 |
|
|
NOTE 4: COMMITMENTS AND CONTINGENT LIABILITIES
The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2024. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2019.
As of September 30, 2016 and December 31, 2015, the Company pledged bank deposits of $807 and $133, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained guarantees by the bank for the fulfillment of the Company’s lease commitments of $962 and $283, respectively.
|
NOTE 6: EQUITY INCENTIVE PLAN
In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the “2015 Plan”). The 2015 Plan replaced the 2013 Share Option Plan. Under the 2015 Plan, the Company can issue various types of equity compensation awards such as restricted shares, performance shares, restricted stock units, performance units, long-term cash award and other share-based awards.
The options granted under the 2015 Plan generally have a four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan that are cancelled or forfeited before expiration become available for future grant.
As of September 30, 2016, 12,717,460 ordinary shares were available for grant under the 2015 Plan.
A summary of the status of the Company’s option plans as of September 30, 2016 and changes during the period then ended is presented below:
|
|
Nine months ended September 30, |
|
|||||
|
|
Unaudited |
|
|||||
|
|
Number of options |
|
|
Weighted average exercise price |
|
||
Outstanding at beginning of year |
|
|
10,134,829 |
|
|
$ |
8.20 |
|
Granted |
|
|
2,363,575 |
|
|
|
13.61 |
|
Exercised |
|
|
(828,787 |
) |
|
|
0.24 |
|
Forfeited and cancelled |
|
|
(133,364 |
) |
|
|
17.19 |
|
|
|
|
|
|
|
|
|
|
Outstanding as of September 30, 2016 |
|
|
11,536,253 |
|
|
|
9.78 |
|
|
|
|
|
|
|
|
|
|
Exercisable options |
|
|
5,887,411 |
|
|
|
5.05 |
|
|
|
|
|
|
|
|
|
|
Vested and expected to vest |
|
|
11,329,415 |
|
|
$ |
9.71 |
|
In September 2015, the Company adopted an employee share purchase plan (“ESPP”) to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. In the United States, the ESPP is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code and the provisions of the ESPP will be construed in a manner consistent with the requirements of such section. The Company began its offerings under the ESPP on August 1, 2016. As of September 30, 2016, 1,667,785 ordinary shares were available to be purchased by eligible employees under the ESPP and no shares had been issued under the ESPP.
The fair value of equity-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions:
|
|
Nine months ended September 30, |
|
|
Year ended December 31, |
|||||
|
|
2016 |
|
|
2015 |
|
|
2015 |
||
|
|
Unaudited |
|
|
Audited |
|||||
Stock Option Plans |
|
|
|
|
|
|
|
|
|
|
Expected term (years) |
|
6.25 |
|
|
|
6.25 |
|
|
6.25 |
|
Expected volatility |
|
59.12%-61.65% |
|
|
62.50% - 65.80% |
|
|
59.00%-65.80% |
||
Risk-free interest rate |
|
1.23%-1.88% |
|
|
1.75% - 1.90% |
|
|
1.74%-2.05% |
||
Dividend yield |
|
0% |
|
|
0% |
|
|
0% |
||
ESPP |
|
|
|
|
|
|
|
|
|
|
Expected term (years) |
|
0.42 |
|
|
- |
|
|
- |
||
Expected volatility |
|
|
70.45 |
% |
|
- |
|
|
- |
|
Risk-free interest rate |
|
|
0.40 |
% |
|
- |
|
|
- |
|
Dividend yield |
|
0% |
|
|
- |
|
|
- |
The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2016 and 2015 and the year ended December 31, 2015 was:
|
|
Three months ended September 30, |
|
|
Nine months ended September 30, |
|
|
Year ended December 31, |
|
|||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
|
2015 |
|
|||||
|
|
Unaudited |
|
|
Unaudited |
|
|
Audited |
|
|||||||||||
Cost of revenues |
|
$ |
160 |
|
|
$ |
35 |
|
|
$ |
471 |
|
|
$ |
54 |
|
|
$ |
174 |
|
Research, development and clinical trials |
|
|
776 |
|
|
|
668 |
|
|
|
2,378 |
|
|
|
1,717 |
|
|
|
2,529 |
|
Sales and marketing |
|
|
1,249 |
|
|
|
571 |
|
|
|
3,888 |
|
|
|
1,550 |
|
|
|
2,496 |
|
General and administrative |
|
|
3,441 |
|
|
|
1,654 |
|
|
|
9,982 |
|
|
|
4,051 |
|
|
|
6,661 |
|
Total share-based compensation expense |
|
$ |
5,626 |
|
|
$ |
2,928 |
|
|
$ |
16,719 |
|
|
$ |
7,372 |
|
|
$ |
11,860 |
|
|
NOTE 7: SUPPLEMENTAL INFORMATION
The Company operates in a single reportable segment.
The following table presents long-lived assets by location:
|
|
September 30, |
|
|
December 31, |
|
||
|
|
2016 |
|
|
2015 |
|
||
|
|
Unaudited |
|
|
Audited |
|
||
United States |
|
$ |
11,792 |
|
|
$ |
6,600 |
|
Switzerland |
|
|
3,769 |
|
|
|
4,204 |
|
Israel |
|
|
1,934 |
|
|
|
1,376 |
|
Others |
|
|
433 |
|
|
|
401 |
|
Total |
|
$ |
17,928 |
|
|
$ |
12,581 |
|
The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
Year ended December 31, |
|
|||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
|
2015 |
|
|||||
|
|
Unaudited |
|
|
Unaudited |
|
|
Audited |
|
|||||||||||
United States |
|
$ |
18,131 |
|
|
$ |
8,546 |
|
|
$ |
46,264 |
|
|
$ |
19,710 |
|
|
$ |
30,961 |
|
EMEA |
|
|
3,519 |
|
|
|
407 |
|
|
|
6,296 |
|
|
|
994 |
|
|
|
2,070 |
|
Japan |
|
|
24 |
|
|
|
- |
|
|
|
86 |
|
|
|
- |
|
|
|
56 |
|
Total |
|
$ |
21,674 |
|
|
$ |
8,953 |
|
|
$ |
52,646 |
|
|
$ |
20,704 |
|
|
$ |
33,087 |
|
|
NOTE 8: LONG-TERM LOAN, NET OF DISCOUNT AND ISSUANCE COSTS
In January 2015, the Company entered into a five-year term loan agreement (the “Term Loan Credit Facility”) with a lender to draw up to $100,000. In January 2015, the Company drew $25,000 from the lender. The Company had the option to draw the remaining $75,000 at its option at any time through June 30, 2016. On June 30, 2016, the Company provided to the lender a drawdown notice for the remaining $75,000, and it received funds in July 2016. As of September 30, 2016, there is $100,000 outstanding under the Term Loan Credit Facility.
Interest on the outstanding loan is 10% annually, payable quarterly in arrears. In addition, there is a 1.5% funding fee payable on the amount drawn on the funding date, a 0.75% pay-down fee on all principal amount repayments to be paid on the date such payments of principal are made and a pre-payment fee of 3.0%, 2.0% or 1.0% if the Company prepays outstanding loan amounts prior to the first, second or third year anniversaries, respectively, from the initial funding date. The entire outstanding principal loan is due in January 2020. The loan is secured by a first priority security interest in substantially all assets of the Company. The Term Loan Credit Facility sets forth certain affirmative and negative covenants with which the Company must comply on a quarterly basis through the term of the loan. As of September 30, 2016, the Company was in compliance with such covenants.
The total discount of $2,019 and additional issuance costs of $2,744 are presented net of the loan and are amortized to interest expense over the term of the loan using the effective interest method.
|
NOTE 9: IMPAIRMENT OF FIELD EQUIPMENT
The Company received U.S. Food and Drug Administration approval on its Premarket Approval supplement application to market its second generation Optune System in the United States on July 13, 2016. The Company made the second generation Optune System available to all patients in the United States during the quarter ended September 30, 2016. Manufacturing of the first generation Optune System has been terminated. For the nine months ended September 30, 2016, the Company recorded an impairment loss in the second quarter with respect to the write-off of first generation Optune System field equipment (finished goods and production stage) in the amount of $6,412, including advances for materials purchased and liabilities incurred to vendors of $1,582 that are not recoverable, presented in cost of revenues. The Company does not expect the conversion to result in an additional material impairment charge in the future.
|
Recently Issued Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.
In March 2016, FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.
In April 2016, FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASU 2016-10 covers two specific topics: performance obligations and licensing. This amendment includes guidance on immaterial promised goods or services, shipping or handling activities, separately identifiable performance obligations, functional or symbolic intellectual property licenses, sales-based and usage-based royalties, license restrictions (time, use, geographical) and licensing renewals. In addition, in May 2016, FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The Company is currently evaluating the impact of the adoption of both revenue standards on its consolidated financial statements.
In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. ASU 2016-13 also applies to employee benefit plan accounting, with an effective date of the first quarter of fiscal 2022. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and employee benefit plans’ accounting.
In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayment or extinguishment costs, the maturing of a zero coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The retrospective transition method, requiring adjustment to all comparative periods presented, is required unless it is impracticable for some of the amendments, in which case those amendments would be prospectively adjusted as of the earliest date practicable. The standard is effective on January 1, 2019. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements.
|
Inventories are stated at the lower of cost or market. The weighted average methodology is applied to determine cost. As of September 30, 2016 and December 31, 2015, the Company’s inventories were composed of:
|
|
September 30, |
|
|
December 31, |
|
||
|
|
2016 |
|
|
2015 |
|
||
|
|
Unaudited |
|
|
Audited |
|
||
Raw materials |
|
$ |
4,517 |
|
|
$ |
3,518 |
|
Work in progress |
|
|
9,621 |
|
|
|
4,618 |
|
Finished products |
|
|
9,834 |
|
|
|
5,458 |
|
Total |
|
$ |
23,972 |
|
|
$ |
13,594 |
|
|
A summary of the status of the Company’s option plans as of September 30, 2016 and changes during the period then ended is presented below:
|
|
Nine months ended September 30, |
|
|||||
|
|
Unaudited |
|
|||||
|
|
Number of options |
|
|
Weighted average exercise price |
|
||
Outstanding at beginning of year |
|
|
10,134,829 |
|
|
$ |
8.20 |
|
Granted |
|
|
2,363,575 |
|
|
|
13.61 |
|
Exercised |
|
|
(828,787 |
) |
|
|
0.24 |
|
Forfeited and cancelled |
|
|
(133,364 |
) |
|
|
17.19 |
|
|
|
|
|
|
|
|
|
|
Outstanding as of September 30, 2016 |
|
|
11,536,253 |
|
|
|
9.78 |
|
|
|
|
|
|
|
|
|
|
Exercisable options |
|
|
5,887,411 |
|
|
|
5.05 |
|
|
|
|
|
|
|
|
|
|
Vested and expected to vest |
|
|
11,329,415 |
|
|
$ |
9.71 |
|
The fair value of equity-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions:
|
|
Nine months ended September 30, |
|
|
Year ended December 31, |
|||||
|
|
2016 |
|
|
2015 |
|
|
2015 |
||
|
|
Unaudited |
|
|
Audited |
|||||
Stock Option Plans |
|
|
|
|
|
|
|
|
|
|
Expected term (years) |
|
6.25 |
|
|
|
6.25 |
|
|
6.25 |
|
Expected volatility |
|
59.12%-61.65% |
|
|
62.50% - 65.80% |
|
|
59.00%-65.80% |
||
Risk-free interest rate |
|
1.23%-1.88% |
|
|
1.75% - 1.90% |
|
|
1.74%-2.05% |
||
Dividend yield |
|
0% |
|
|
0% |
|
|
0% |
||
ESPP |
|
|
|
|
|
|
|
|
|
|
Expected term (years) |
|
0.42 |
|
|
- |
|
|
- |
||
Expected volatility |
|
|
70.45 |
% |
|
- |
|
|
- |
|
Risk-free interest rate |
|
|
0.40 |
% |
|
- |
|
|
- |
|
Dividend yield |
|
0% |
|
|
- |
|
|
- |
The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2016 and 2015 and the year ended December 31, 2015 was:
|
|
Three months ended September 30, |
|
|
Nine months ended September 30, |
|
|
Year ended December 31, |
|
|||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
|
2015 |
|
|||||
|
|
Unaudited |
|
|
Unaudited |
|
|
Audited |
|
|||||||||||
Cost of revenues |
|
$ |
160 |
|
|
$ |
35 |
|
|
$ |
471 |
|
|
$ |
54 |
|
|
$ |
174 |
|
Research, development and clinical trials |
|
|
776 |
|
|
|
668 |
|
|
|
2,378 |
|
|
|
1,717 |
|
|
|
2,529 |
|
Sales and marketing |
|
|
1,249 |
|
|
|
571 |
|
|
|
3,888 |
|
|
|
1,550 |
|
|
|
2,496 |
|
General and administrative |
|
|
3,441 |
|
|
|
1,654 |
|
|
|
9,982 |
|
|
|
4,051 |
|
|
|
6,661 |
|
Total share-based compensation expense |
|
$ |
5,626 |
|
|
$ |
2,928 |
|
|
$ |
16,719 |
|
|
$ |
7,372 |
|
|
$ |
11,860 |
|
|
The following table presents long-lived assets by location:
|
|
September 30, |
|
|
December 31, |
|
||
|
|
2016 |
|
|
2015 |
|
||
|
|
Unaudited |
|
|
Audited |
|
||
United States |
|
$ |
11,792 |
|
|
$ |
6,600 |
|
Switzerland |
|
|
3,769 |
|
|
|
4,204 |
|
Israel |
|
|
1,934 |
|
|
|
1,376 |
|
Others |
|
|
433 |
|
|
|
401 |
|
Total |
|
$ |
17,928 |
|
|
$ |
12,581 |
|
The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
Year ended December 31, |
|
|||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
|
2015 |
|
|||||
|
|
Unaudited |
|
|
Unaudited |
|
|
Audited |
|
|||||||||||
United States |
|
$ |
18,131 |
|
|
$ |
8,546 |
|
|
$ |
46,264 |
|
|
$ |
19,710 |
|
|
$ |
30,961 |
|
EMEA |
|
|
3,519 |
|
|
|
407 |
|
|
|
6,296 |
|
|
|
994 |
|
|
|
2,070 |
|
Japan |
|
|
24 |
|
|
|
- |
|
|
|
86 |
|
|
|
- |
|
|
|
56 |
|
Total |
|
$ |
21,674 |
|
|
$ |
8,953 |
|
|
$ |
52,646 |
|
|
$ |
20,704 |
|
|
$ |
33,087 |
|
|
|
|
|
|
|
|
|
|
|